A Trial of HRS-6213 in Healthy Subjects and Patients With Solid Tumors
A phase 1/2 trial of HRS-6213 in advanced solid tumours, run by Jiangsu HengRui Medicine Co., Ltd., now recruiting.
Overview
A Trial of HRS-6213 in Healthy Subjects and Patients With Solid Tumors is a phase 1/2 interventional study registered as NCT07070349 by Jiangsu HengRui Medicine Co., Ltd., with 48 participants planned, started 2025-07-10 and due to reach its primary completion in 2026-01. Interventions recorded: HRS-6213.
Setting
A Phase I/II Clinical Study to Evaluate the Safety, Radiation Dosimetry, Pharmacokinetics, and Preliminary Diagnostic Efficacy of HRS-6213 in Healthy Subjects and Patients With Solid Tumors
Phase
Phase 1/2
Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Registry
Enrolled
48 enrolled
Nothing links here yet.